The Missing Lynx

Premium

Lynx Therapeutics is misnamed, low on funds, and short on marketing talent. But if it can overcome all that, it has one hell of a product to sell you

 

By Aaron J. Sender

 

“One of the most fulfilling things in this job,” says Lynx Therapeutics CEO Norrie Russell, whose role is to enlighten outsiders about his company’s product, “is when they stop being glassy-eyed and say, ‘Holy shit! I’ve got it.’”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.